z-logo
open-access-imgOpen Access
Evinacumab — an ANGPTL3 inhibitor; a new drug in the treatment of lipid disorders. Review on the literature and clinical studies
Author(s) -
Stanisław Surma,
Monika Romańczyk,
Krzysztof J. Filipiak‬
Publication year - 2021
Publication title -
folia cardiologica
Language(s) - English
Resource type - Journals
eISSN - 2353-7760
pISSN - 2353-7752
DOI - 10.5603/fc.2021.0005
Subject(s) - medicine , diabetes mellitus , type 2 diabetes , endocrinology , drug , lipid metabolism , obesity , clinical trial , disease , metabolic syndrome , pharmacology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom